Editor's Highlights — July 2026
International Journal of Dermatology · 2026-07 · 65 (7) · 1355-1356
DOI: 10.1111/ijd.70518 ↗Kurz gefasst
Editorial in der Zeitschrift International Journal of Dermatology, online erschienen am 27.05.2026. Verfasst von Lajos Kemény. Beteiligte Einrichtung: Department of Dermatology and Allergology, University of Szeged, Szeged, Hungary. Hauptthemen laut MEDLINE: Autoimmune Diseases, Skin Diseases, Vesiculobullous, Immune Checkpoint Inhibitors. Die Arbeit nennt 5 Literaturangaben.
Abstract (Originalsprache)
Targeted therapeutic advances in autoimmune blistering diseases have renewed attention to diagnostic precision, disease classification, and clinically relevant subgroups. In this issue, we focus on two aspects of this evolving field: recent developments in the diagnostics of autoimmune blistering diseases and the clinical features of checkpoint inhibitor–associated autoimmune blistering diseases and their treatment options. These contributions illustrate how therapeutic innovation, diagnostic progress, and recognition of emerging clinical contexts are closely interconnected.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Dermatology and Allergology, University of Szeged, Szeged, Hungary.
ORCID-Profile: Lajos Kemény
Zitieren
APA
Kemény, L. (2026). Editor's Highlights — July 2026. International Journal of Dermatology, 65(7), 1355-1356. https://doi.org/10.1111/ijd.70518
Vancouver
Kemény L. Editor's Highlights — July 2026. International Journal of Dermatology. 2026;65(7):1355-1356. doi:10.1111/ijd.70518
BibTeX
@article{Kemny2026,
author = {Kemény, Lajos},
title = {Editor's Highlights — July 2026},
journal = {International Journal of Dermatology},
year = {2026},
volume = {65},
number = {7},
pages = {1355--1356},
doi = {10.1111/ijd.70518}
}
EUVIMED